Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted inside cells to SN‑38, an active metabolite that binds to the DNA‑topoisomerase I complex. This prevents the re‑ligation of single‑strand DNA breaks during replication, causing permanent DNA damage and triggering cancer cell death.

The dosing of Irinotecan Accord is individualized and determined by the prescribing oncologist based on factors such as cancer type, treatment protocol, patient weight, and organ function. Specific regimens are not disclosed here.

Irinotecan is classified as Pregnancy Category D, indicating evidence of fetal risk. It is contraindicated during pregnancy and should not be used by breastfeeding mothers because it may be excreted in milk and harm the infant.

To request Irinotecan Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

The primary alternative within the same class is topotecan, another topoisomerase I inhibitor. Irinotecan generally has a broader indication profile, especially for colorectal cancer, and is often combined with fluoropyrimidines. Topotecan is used more frequently for small‑cell lung cancer and ovarian cancer, with differing toxicity patterns.

Irinotecan Accord should be stored at controlled room temperature, below 25 °C, in its original packaging to protect from light and moisture. The product must be reconstituted and administered by qualified healthcare professionals following aseptic technique.

Irinotecan Accord is administered intravenously by a qualified healthcare provider, usually as an infusion over a specified period. The exact infusion rate and schedule are determined by the treating physician and may be adjusted based on patient tolerance and response.

The most serious risks include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea or colitis, cholinergic syndrome, hypersensitivity reactions, and hepatic toxicity. Prompt medical evaluation is essential if any of these events occur.

Irinotecan Accord should not be used in patients with known hypersensitivity to irinotecan or its excipients, in pregnant women, or in individuals with severe hepatic impairment without dose adjustment. Caution is also advised for patients with pre‑existing severe bone‑marrow suppression.